Last reviewed · How we verify
Investigational RSV vaccine 6
Investigational RSV vaccine 6 is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | Investigational RSV vaccine 6 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older (PHASE3)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older (PHASE1, PHASE2)
- Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years (PHASE1)
- Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age (PHASE1)
- Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older (PHASE1)
- A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years (PHASE1)
- Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational RSV vaccine 6 CI brief — competitive landscape report
- Investigational RSV vaccine 6 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Investigational RSV vaccine 6
What is Investigational RSV vaccine 6?
Investigational RSV vaccine 6 is a Biologic drug developed by GlaxoSmithKline.
Who makes Investigational RSV vaccine 6?
Investigational RSV vaccine 6 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Investigational RSV vaccine 6 in?
Investigational RSV vaccine 6 is in Phase 1.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Compare: Investigational RSV vaccine 6 vs similar drugs
- Pricing: Investigational RSV vaccine 6 cost, discount & access